Gazyvaro Enters Field Against Arzerra As NICE Gives It Nod In CLL
This article was originally published in The Pink Sheet Daily
Executive Summary
An undisclosed discount and additional data have prompted the British cost watchdog to change its mind and recommend Roche’s Gazyvaro in chronic lymphocytic leukemia, but it will have to move fast to secure market share.